Handelsbanken Fonder AB Cuts Stake in DexCom, Inc. $DXCM

Handelsbanken Fonder AB trimmed its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 41.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 320,124 shares of the medical device company’s stock after selling 230,974 shares during the period. Handelsbanken Fonder AB’s holdings in DexCom were worth $21,247,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of DXCM. Brighton Jones LLC grew its position in DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after purchasing an additional 11,946 shares during the last quarter. Integrated Wealth Concepts LLC lifted its stake in DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after acquiring an additional 196 shares during the period. Empowered Funds LLC lifted its stake in DexCom by 5.4% during the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after acquiring an additional 436 shares during the period. Focus Partners Wealth lifted its stake in DexCom by 13.2% during the 1st quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after acquiring an additional 841 shares during the period. Finally, NewEdge Advisors LLC lifted its stake in DexCom by 1.4% during the 2nd quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock valued at $1,681,000 after acquiring an additional 258 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on DXCM shares. Barclays restated an “underweight” rating and set a $64.00 target price (down from $67.00) on shares of DexCom in a research note on Monday. Wells Fargo & Company lowered their target price on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a research note on Friday, February 13th. Evercore upgraded shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 target price on the stock in a research note on Tuesday, March 24th. Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Finally, Raymond James Financial set a $81.00 target price on shares of DexCom in a research note on Friday, May 1st. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $82.21.

Insider Activity at DexCom

In other news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total value of $107,168.00. Following the transaction, the executive vice president owned 111,204 shares in the company, valued at $7,010,300.16. This represents a 1.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total transaction of $60,730.12. Following the completion of the transaction, the director owned 25,007 shares in the company, valued at $1,500,670.07. This trade represents a 3.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 6,112 shares of company stock worth $379,990 in the last quarter. Company insiders own 0.28% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $71.44 on Thursday. The firm’s 50 day moving average price is $63.38 and its 200-day moving average price is $65.84. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $27.57 billion, a PE ratio of 30.53, a price-to-earnings-growth ratio of 1.11 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the prior year, the business earned $0.32 EPS. The business’s quarterly revenue was up 15.0% on a year-over-year basis. Equities research analysts expect that DexCom, Inc. will post 2.57 EPS for the current year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.